MELBOURNE, AUSTRALIA–Celgene Pty Ltd and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia. Under the terms of the agreement, Juno will assist with the commercial management of Vidaza® in Australia.

“By combining forces with Juno Pharmaceuticals, we are complementing our innovative product with a strong national key account management team that has relationships across the hospital market,” said George Varkanis, Celgene Vice President and Managing Director (Australia and New Zealand).

The partnership continues the trend for Juno Pharmaceuticals in partnering with leading global pharmaceutical companies. It follows a recent announcement that Juno Pharmaceuticals made with Photocure ASA to bring the unique product Hexvix® to the Australian and New Zealand markets.

“We look forward to delivering a strong partnership model with Celgene on Vidaza® and exploring any opportunities that exist throughout the products lifecycle,” said Juno Pharmaceuticals CEO George Katsanos. Financial details of the joint venture were not disclosed.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com.

About Juno Pharmaceuticals

Juno Pharmaceuticals is a rapidly growing global health care company with a focus on bringing innovative pharmaceuticals to hospitals and health care specialists.

With a primary focus on the hospital and health care specialist market, Juno has access to a range of products across multiple therapeutic areas including biosimilars and antibiotics. An extensive global network of manufacturers also allows us to source niche, life saving products for our Australasian customers. Our experienced Hospital based Key Account Management team offers our partner companies alternate portfolio solutions for a range of maturing products. Juno is also engaged in bringing to market patent protected products.

For more information, please visit www.junopharm.com.au